轩竹生物转战港股:分拆自四环医药,上半年亏损超1亿元

澎湃新闻
27 Nov 2024

今年5月终止科创板上市后,四环医药(0460.HK)子公司轩竹生物转向冲刺港股。11月25日,港交所官网显示,轩竹生物科技股份有限公司(简称“轩竹生物”)递交上市申请。这一转战港股的消息并不突然。11月12日,四环医药就曾公告,建议分拆轩竹生物的股份并于联交所主板上市,且公司已取得联交所关于其根据上市规则第15项应用指引建议分拆轩竹生物的批准。同时,四环医药以总价约3.08亿元进一步收购轩竹生物约...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10